Porphyria Cutanea Tarda clinical trials at UCSF
1 research study open to eligible people

• Harvoni Treatment Porphyria Cutanea Tarda

  open to eligible people ages 18 years and up

  In the medical literature there case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested. Therefore, the purpose of this study is to assess whether Harvoni alone is an effective therapy of active PCT in patients with Chronic Hepatitis C.

  San Francisco, California and other locations

Last updated: June 24, 2019